此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

OXytocin For Opioid Respiratory Depression (OXFORD)

2026年11月9日 更新者:Vsevolod Polotsky、George Washington University

A Prospective, Single-center, Randomized, Double-blinded Study to Evaluate the Therapeutic Efficacy of Intranasal Oxytocin in Decreasing the Severity of Sleep Disordered Breathing, Pain Perception, Opioid Dose and Drug Liking in Patients on Chronic Opioid Therapy for Chronic Pain

Opioid medications are a significant component of the management of chronic pain. Chronic use of opioids disrupts sleep architecture and cause respiratory depression, which is particularly prevalent during sleep. Chronic opioids induce sleep disordered breathing (SDB) including sleep hypoventilation, central sleep apnea and obstructive sleep apnea (OSA). It was previously shown that oxytocin can treat SDB. There is emerging evidence that oxytocin can treat substance use disorder and has analgesic properties. Oxytocin efficacy of prevention of respiratory depression after acute opioid use will be examined as well as oxytocin efficacy in chronic opioid use.

研究概览

详细说明

Intranasal oxytocin to prevent opioid-induced respiratory depression, reduce pain and the opioid dose in patients on chronic opioids (OXytocin For Opioid Respiratory Depression). OXFORD will test in a double blinded, placebo-controlled phase 2 clinical trial, the therapeutic efficacy of OXYTOCIN in decreasing A) the severity of sleep disordered breathing (SDB); B) pain perception, C) the opioid dose and D) drug liking in patients on chronic opioid therapy for chronic pain. Opioid medications are a significant component of the management of chronic pain. Chronic use of opioids disrupts sleep architecture and cause respiratory depression, which is particularly prevalent during sleep. Chronic opioids induce SDB including sleep hypoventilation, central sleep apnea and OSA. It was previously shown that OXYTOCIN can treat Sleep Disordered Breathing (SDB). There is emerging evidence that OXYTOCIN can treat substance use disorder and has analgesic properties. OXFORD will examine OXYTOCIN efficacy for prevention of respiratory depression after acute opioid use.

研究类型

介入性

注册 (估计的)

100

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. ≥ 18 years of age
  2. Treated for chronic pain with ≥ 30 milligram morphine equivalent (MME)
  3. Able and willing to provide informed consent
  4. Women of childbearing potential will be required to use a highly effective form of contraception in order to be included in the study

Exclusion Criteria:

  1. OSA patients on CPAP therapy
  2. Baseline home sleep testing with > than 10 minutes with a baseline oxygen saturation <=85%
  3. Unstable cardiovascular disease (decompensated CHF, myocardial infarction or revascularization procedures, and unstable arrhythmias)
  4. Uncontrolled hypertension (BP > 190/110)
  5. Chronic Obstructive Pulmonary Disease or another intrinsic lung disease
  6. Chronic sinusitis requiring surgical treatment (except septal deviation)
  7. Chronic muscle weakness
  8. Chronic daytime hypoxemia (PaO2 < 70) or hypercapnia (PaCO2 ≥ 45 mmHg)
  9. Chronic supplemental oxygen use
  10. Renal failure on dialysis
  11. Diabetes mellitus requiring insulin
  12. Diabetic neuropathy
  13. Previous surgery for OSA (laser-assisted uvulopalatoplasty, LAUP or uvulopalatopharyngoplasty)
  14. Hypoglossal nerve stimulator
  15. Allergy to oxytocin
  16. Pregnancy
  17. Premenopausal women, who are not on birth control
  18. Any change in non-opioid medications and non-pharmacological interventions during the OXYTOCIN trial

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
有源比较器:Intranasal Oxytocin

Intranasal oxytocin

Intranasal oxytocin dose of 40 international units

安慰剂比较:Intranasal Placebo

Intranasal placebo

This is a placebo comparator intranasal spray

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Hypopnea on home sleep testing
大体时间:Beginning of study (Day 1, baseline) and the night before day 28 visit

Number of hypopnea events on home sleep testing

Beginning of study (Day 1, baseline) and the night before day 28 visit
Oxytocin Level
大体时间:During day 28 visit

Urinary level of oxytocin

During day 28 visit
Respiratory Rate
大体时间:Baseline (Day 1) and second sleep apnea testing (the night before day 28 visit)

Duration of significant increases in respiratory rate

Baseline (Day 1) and second sleep apnea testing (the night before day 28 visit)
Short form McGill Questionnaire
大体时间:Day 1 and Day 30 of study

0-45, higher is more pain

Day 1 and Day 30 of study
Visual Analogue Pain Scale
大体时间:Day 1 and Day 30 of study

0-10, higher is more pain

Day 1 and Day 30 of study
Drug liking and high questionnaire
大体时间:Day 1 and Day 30 of study

0-16, higher is more drug effect from pain medications

Day 1 and Day 30 of study
Short form brief pain inventory
大体时间:Day 1 and Day 30 of study

0-120, higher is more pain

Day 1 and Day 30 of study

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年5月15日

初级完成 (估计的)

2029年7月14日

研究完成 (估计的)

2030年7月14日

研究注册日期

首次提交

2026年10月22日

首先提交符合 QC 标准的

2026年11月9日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • OXFORD-GWU-2
  • UG3DA062506-02 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅